^99mTc-Sestamibi SPECT/CT and histopathological features of oncocytic renal neoplasia

References

• van Oostenbrugge TJ, Fütterer JJ, Mulders PFA. Diagnostic imaging for solid renal tumors: a pictorial review. Kidney Cancer. 2018;2(2):79–93.
   PubMedGoogle Scholar
• Kim JH, Li S, Khandwala Y, et al. Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg. 2019;154(3):225–231.
   PubMed Web of Science ®Google Scholar
• Morshid A, Duran ES, Choi WJ, et al. A concise review of the multimodality imaging features of renal cell carcinoma. Cureus. 2021;13(2):e13231.
   PubMed Web of Science ®Google Scholar
• Zhang GMY, Shi B, Xue HD, et al. Can quantitative CT texture analysis be used to differentiate subtypes of renal cell carcinoma? Clin Radiol. 2019;74(4):287–294.
   PubMed Web of Science ®Google Scholar
• Wilson MP, Katlariwala P, Murad MH, et al. Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. Abdom Radiol. 2020;45(8):2532–2541.
   PubMed Web of Science ®Google Scholar
• Abdessater M, Kanbar A, Comperat E, et al. Renal oncocytoma: an algorithm for diagnosis and management. Urology. 2020;143:173–180.
   PubMed Web of Science ®Google Scholar
• Su ZT, Patel HD, Huang MM, et al. Cost-effectiveness analysis of 99mTc-sestamibi SPECT/CT to guide management of small renal masses. Eur Urol Focus. 2021;7(4):827–834.
   PubMedGoogle Scholar
• Udager AM, Mehra R. Morphologic, molecular, and taxonomic evolution of renal cell carcinoma a conceptual perspective with emphasis on updates to the 2016 world health organization classification. Arch Pathol Lab Med. 2016;140(10):1026–1037.
   PubMed Web of Science ®Google Scholar
• Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: the genitourinary pathology society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34(6):1167–1184.
   PubMed Web of Science ®Google Scholar
• Gill AJ, Moch H, Amin MB, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs — Part A: Renal, Penile, and Testicular Tumours; 2022.
   Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
   PubMed Web of Science ®Google Scholar
• Ruiz-Cordero R, Rao P, Li L, et al. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma. Mod Pathol. 2019;32(11):1698–1707.
   PubMed Web of Science ®Google Scholar
• Hes O, Trpkov K. Do we need an updated classification of oncocytic renal tumors? Mod Pathol. 2022;35(9):1140–1150.
   PubMedGoogle Scholar
• Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75(2):174–184.
   PubMed Web of Science ®Google Scholar
• Kapur P, Gao M, Zhong H, et al. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol. 2022;35(3):333–343.
   PubMed Web of Science ®Google Scholar
• Morini A, Drossart T, Timsit MO, et al. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Mod Pathol. 2022;35(3):352–360.
   PubMed Web of Science ®Google Scholar
• Mansoor M, Siadat F, Trpkov K. Low-grade oncocytic tumor (LOT)-a new renal entity ready for a prime time: an updated review. Histol Histopathol. 2022;37(5):405–413.
   PubMed Web of Science ®Google Scholar
• Tzortzakakis A, Gustafsson O, Karlsson M, et al. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT. EJNMMI Res. 2017;7(1):29.
   PubMedGoogle Scholar
• Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of 99mTc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69(3):413–416.
   PubMed Web of Science ®Google Scholar
• Rowe SP, Gorin MA, Gordetsky J, et al. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med. 2015;40(4):309–313.
   PubMed Web of Science ®Google Scholar
• Tzortzakakis A, Holstensson M, Hagel E, et al. Intra- and interobserver agreement of SUV SPECT quantitative SPECT/CT processing software, applied in clinical settings for patients with solid renal tumors. J Nucl Med Technol. 2019;47(3):258–262.
   PubMed Web of Science ®Google Scholar
• Papathomas T, Tzortzakakis A, Sun N, et al. In situ metabolomics expands the spectrum of renal tumours positive on 99m Tc-sestamibi single photon emission computed tomography/computed tomography examination. Eur Urol Open Sci. 2020;22:88–96.
   PubMedGoogle Scholar
• Wilson MP, Katlariwala P, Abele J, et al. A review of 99mTc-sestamibi SPECT/CT for renal oncocytomas: a modified diagnostic algorithm. Intractable Rare Dis Res. 2022;11(2):46–51.
   PubMed Web of Science ®Google Scholar
• Dickson J, Ross J, Vöö S. Quantitative SPECT: the time is now. EJNMMI Phys. 2019;6(1):4–7.
   PubMedGoogle Scholar
• Chan C, Liu H, Grobshtein Y, et al. Noise suppressed partial volume correction for cardiac SPECT/CT. Med Phys. 2016;43(9):5225–5239.
   PubMed Web of Science ®Google Scholar
• Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(6):668–680.
   PubMed Web of Science ®Google Scholar
• McIntosh AG, Ristau BT, Ruth K, et al. Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and >5-yr clinical outcomes. Eur Urol. 2018;74(2):157–164.
   PubMed Web of Science ®Google Scholar
• England RW, Sheikhbahaei S, Solomon AJ, et al. When more is better: underused advanced imaging exams that can improve outcomes and reduce cost of care. Am J Med. 2021;134(7):848–853.e1.
   PubMed Web of Science ®Google Scholar
• Akgul M, Al-Obaidy KI, Cheng L, et al. Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol. 2021:jclinpath-2021-207478.
   Web of Science ®Google Scholar
• Ishikawa N, Kimura N, Yoshida T, et al. A case of low-grade oncocytic tumor/chromophobe renal cell carcinoma (oncocytic variant) of the kidney. Case Rep Pathol. 2021;2021:6684774–6684777.
   Web of Science ®Google Scholar
• Mohanty SK, Satapathy A, Aggarwal A, et al. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod Pathol. 2022;35(3):361–375.
   PubMed Web of Science ®Google Scholar
• Patel HD, Druskin SC, Rowe SP, et al. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017;119(5):661–666.
   PubMed Web of Science ®Google Scholar
• Kim M, Joo JW, Lee SJ, et al. Comprehensive immunoprofiles of renal cell carcinoma subtypes. Cancers. 2020;12(3):602–616.
   PubMed Web of Science ®Google Scholar
• Skala SL, Wang X, Zhang Y, et al. Next-generation RNA sequencing–based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78(1):63–74.
   PubMed Web of Science ®Google Scholar
• Montironi R, Gasparrini S, Cimadamore A, et al. Variants and variations in epithelial renal cell tumors in adults: the pathologist’s point of view. Eur Urol Suppl. 2017;16(12):232–240.
   Web of Science ®Google Scholar
• Erlmeier F, Feuchtinger A, Borgmann D, et al. Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes. Histochem Cell Biol. 2015;144(2):147–156.
   PubMed Web of Science ®Google Scholar
• Poté N, Vieillefond A, Couturier J, et al. Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas. Virchows Arch. 2013;462(6):633–638.
   PubMed Web of Science ®Google Scholar
• Andeen NK, Qu X, Antic T, et al. Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas. Arch Pathol Lab Med. 2019;143(4):494–504.
   PubMed Web of Science ®Google Scholar
• McGillivray PD, Ueno D, Pooli A, et al. Distinguishing benign renal tumors with an oncocytic gene expression (ONEX) classifier. Eur Urol. 2021;79(1):107–111.
   PubMed Web of Science ®Google Scholar
• Buck A, Ly A, Balluff B, et al. High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples. J Pathol. 2015;237(1):123–132.
   PubMed Web of Science ®Google Scholar
• Kravtsov O, Gupta S, Cheville JC, et al. Low-Grade oncocytic tumor of kidney (CK7-Positive, CD117-Negative): incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol. 2021;114:9–18.
   PubMed Web of Science ®Google Scholar